मैट्रिक्स
 
 
मंगलम ड्रग्स एंड ऑर्गेनिक्स > कंपनी इतिहास > Pharmaceuticals > कंपनी इतिहास का मंगलम ड्रग्स एंड ऑर्गेनिक्स - बीएसई: 532637, NSE: MANGALAM

मंगलम ड्रग्स एंड ऑर्गेनिक्स

बीएसई: 532637  |  NSE: MANGALAM  |  ISIN: INE584F01014  |  Pharmaceuticals

कंपनी इतिहास - मंगलम ड्रग्स एंड ऑर्गेनिक्स
A. HISTORY AND BACKGROUND
 
 Mangalam Drugs & Organics Limited (Mangalam) is a part of the
 Mangalam
 Group, promoted by Dhoot family in 1972 as Advent Pharma Private
 Limited with a view to set up a plant for manufacture of organic and
 inorganic chemicals. On April 1, 1996 three other group companies
 i.e.
 Mangalam Organics Private Limited, Shree Mangalam Pharma Private
 Limited and Mangalam Rasayan Private Limited were merged with Advent
 Pharma Private Limited. Under the scheme of arrangement approved by
 the
 Honorable High Court, Mumbai and Gujarat, the entire chemical
 division
 of MOPL, MRPL and SMPPL was transferred to and vested in MDOL as a
 going concern free from all encumbrances and on that basis MDOL
 issued
 one fully paid equity share of MDOL for every twenty fully paid
 equity
 shares of MOPL, twelve fully paid equity shares of MDOL for every
 five
 fully paid equity shares of MRPL and twenty-seven fully paid equity
 shares of MDOL for every five fully paid equity shares of SMPPL to
 the
 share holders of MOPL, MRPL and SMPPL respectively. Subsequent to
 this
 merger, the name of Advent Pharma Private Limited was changed to
 Mangalam Drugs and Organics Private Limited. In September 1997, it
 became a deemed public limited company in terms of Section 43A of
 the
 Companies Act, 1956.  In 2001, the company was converted into a full
 fledged public limited company in terms of Special Resolution passed
 on
 August 10th, 2001.
 
 The company has a state of art multi-product manufacturing
 facilities
 at Vapi in Gujarat and Sangamner in Maharashtra for production of
 bulk
 drugs, perfumery chemicals, inorganic chemicals and disperse dyes
 intermediaries with a strong in-house Research and Development base.
 
 MDOL is an ISO 9001 certified company, with a WHO GMP Certificate
 (since expired, has applied for renewal) for its bulk drugs
 manufacturing plant, implying that the company carries out good
 manufacturing practices, which is an important tool for promoting
 its
 exports. It enjoys a strong brand name in the domestic market with
 over
 three decades of experience in the industry with a wide and
 satisfied
 customer base.
 
 Company's manufacturing facility at Plot No. 187, Vapi has received
 Certification of Suitability dated 27th September 2004, from
 European
 Directorate for the Quality of Medicine (EDQM) for the production of
 an
 existing product, Nimesulide.
 
 In the year 2003-2004, the bulk drug production capacity of the
 Company
 was increased from 350 MTPA to 600 MTPA. During the current year,
 the
 capacity is being further enhanced to 960 MTPA.Presently various
 bulk
 drugs, other drug intermediates and specialty chemicals such as
 Nimesulide, 4-M.E.P., Oranger Crystals and DTDBA are being produced
 in
 the production facilities The cost pf expansion of capacity is
 Rs.975
 lacs and the same would be financed through internal
 accruals/unsecured
 loans from promoters to the tune of Rs.325 lacs and balance amount
 of
 Rs.650 lacs being financed by Term Loan from State Bank of India.
 The
 said term loan has been sanctioned by SBI and the company has
 commenced
 drawal of funds.
 
 The company with its proven R & D process, has the ability to
 improve
 processes through process innovation, enhance process yields,
 thereby
 reduce costs, coupled with flexible production process, places it in
 a
 position of strength to cater to the requirement of its customers
 under
 one roof. Thus, the company has been able to carve a place for
 itself
 in the segments it is operating in.
 
 There exists an extremely good market for Anti-Malarial Drugs and
 Aluminium Chloride being produced by the company. It intends to take
 advantage of the estimated demand supply gap in the market and
 capitalize on its present strengths in quality, experience and
 reputation. The Company has a stable and well-established customer
 base
 and flexible distribution network for its products. Recently, the
 Government of India has imposed an anti-dumping duty on import of
 Chloroquine Phosphate vide their Notification No. 14/3/2003- DGAD
 dated
 15th July, 2004, which is likely to result in a major surge in
 demand
 for the product in the local market.
 
 Vision, Mission, Quality Policy & Core Values:
 
 Vision:
 
 * To Be a well respected company in the businesses and geographies
 we
 operate in and
 
 * To Become an admired bulk - drugs (API) manufacturing company with
 strong focus on research.
 
 Mission:
 
 To achieve growth in business by
 
 * Attaining globally competitive cost levels
 * Enhancing the value we deliver to stakeholders
 * Commitments to corporate responsibility
 
 Employees are our strength and we will create an environment that
 fosters achievement, innovation and teamwork.
 
 Quality Policy:
 
 Mangalam is committed to customer satisfaction by offering quality
 products and services meeting their specifications and expectations
 at
 competitive prices by customer - employee - vendor in involvement
 and
 adopting GOOD MANUFACTURING PRACTICES AND QUALITY MANAGEMENT
 SYSTEMS.
 
 It aims to create and maintain safe and healthy working conditions,
 protect the environment, strive for continual improvement of our
 personnel, quality and processes of products and meet regulatory
 requirements.
 
 Core Values:
 
 * Excellence
 * Innovation
 * Fairness
 * Transparency
 * Encouraging Initiative
 
 Key  Strengths:
 
 * Existing company with three decades of experience and expertise in
 its field
 
 * An established brand name
 
 * In-house manufacturing facilities with the state of art process,
 quality control and R & D
 
 * Availability of Pilot Plant
 
 * Proven leadership
 
 * Extensive Marketing network in India and abroad
 
 * Proven R&D capabilities to develop efficient and cost effective
 process
 
 * ISO 9001 certification and WHO-GMP* Certification for CQP Plant at
 the Vapi facility
 
 * Certification of Suitability from European Directorate for the
 Quality of Medicine (EDQM) for the production of an existing
 product,
 Nimesulide
 
 * WHO GMP Certificate has expired and the company has applied for
 renewal of the same.
 
 PRODUCTS AND SERVICES
 
 Products Manufactured by the company are:
 
 BULK DRUGS & INTERMEDIATES
 
 A] ANTIMALARIAL
 
 CHLOROQUINE PHOSPHATE I.P./B.P.
 CHLOROQUINE SULPHATE I.P./B.P.
 AMODIAQUINE HCL USP/IP
 AMODIAQUINE BASE USP
 
 B] ANTIANALGESIC
    NIMESULIDE E.P./B.P.
 
 C] INTERMEDIATES
    4, 7, DICHLORO QUINOLINE
    4 METHOXY ETHYL PHENOL
    META CHLORO ANILINE
    SUCCINIMIDE
    ORTHO PHENOXY ANILINE
    ORTHO PHENOXY METHANE SULFONYL ANILIDE
    3, 4 DICHLORO NITROBENZENE
    ORTHO METHOXY TOLUENE
    4 (2-AMINOETHYL) MORPHOLINE
    PHENYL ETHYL CHLORIDE
 
 INORGANIC/ORGANIC CHEMICALS
 
 ALUMINIUM CHLORIDE (ANHYDROUS)
 PHENOXY ETHANOL
 
 PERFUMERY CHEMICALS
 
 PHENYL ETHYL ALCOHOL
 PHENYL ETHYL METHYL ETHER
 PHENYL ETHYL ACETATE
 ORANGER CRYSTALS (METHYL BETA NAPHTHYL KETONE)
 
 SPECIALITY CHEMICALS
 
 N.N-BIS (2-HYDROXY ETHYL) META TOLUIDINE. (MANGALAM-2)
 N-ETHYL-N-HYDROXY ETHYL-ANILINE. (MANGALAM-15)
 N-HYDROXY ETHYL-N-ETHYL META TOLUIDINE (MANGALAM-21)
 N.N.BIS (2-HYDROXY ETHYL) -PARA TOLUIDINE (MANGALAM-25)
 N.N-BIS (2-HYDROXY PROPYL)-PARA TOLUIDINE. (MANGALAM-26)
 
 DISPERSE DYE INTERMEDIATES
 BY PRODUCTS
 
 ALUMINIUM CHLORIDE (SOLUTION)
 TRISODIUM PHOSPHATE
 SODIUM THIO SULPHATE
 
 PRODUCTS UNDER DEVELOPMENT
 TRICLOSAN
 TRICLORO CARBANILIDE
 AVO BENZONE
 OCTYL METHOXY CINNAMATE
 4 HYDROXY PHENYL ETHYL ALCOHOL
 META HYDROXY ACETOPHENONE
 ARTISUNATE
 ARTIMETER
 ARTIETHER
 
 The company is supplying its products to Indoco Remedies
 Ltd..Nicholas
 Piramal India Ltd, May (India) Laboratories Ltd, Bayer
 Pharmaceuticals,
 Unicure (India) P. Ltd, Cipla The Karnataka state Agarbatthi etc.,to
 name a few.
 
 Key milestones
 
 Key milestones of Mangalam over the years are set out below:
 
 Year   Milestone
 
 1977   First plant for Manufacture of perfumery chemicals at 
        Plot No. 187, GIDC, Vapi was started under the name
        Advent Pharma Pvt. Ltd. (APPL)
 
 1981   A new plant under the name Mangalam Rasayan Pvt. Ltd. 
        (MRPL) was commissioned for manufacture of
        Anhydrous Aluminium Chloride
 
 1984   A new plant was commissioned under the name Shree Mangalam 
        Pharma Pvt. Ltd. (SMPPL) where higher manufacturing capacity 
        of Aromatic Chemicals was created.
 
 1984   The facilities in APPL was re-organised to manufacture the 
        first Bulk Drug in the group namely Metronidazole
        I. P.
 
 1985   The capacity of Anhydrous Aluminium Chloride was doubled
 
 1987   Inorganic chemicals manufacturing capacities were expanded by
 
        putting up a new plant at Sangamner under the
        name Mangalam Inorganics Pvt. Ltd. (MIPL)
 
 1989   A new plant was erected to manufacture Dyes Intermediates at 
        Plot No. 1203, IIIrd Phase, GIDC, Vapi under the
        name Mangalam Organics Private Ltd. (MOPL)
 
 1991   Additional manufacturing capacity for perfumery chemicals was
 
        created under new plant of SMPPL
 
 1994   A New Plant was commissioned for manufacturing of Meta Chloro
 
        Aniline under MRPL
 
 1997   Scheme of arrangement between SMPPL, MOPL and MRPL by 
        transferring their entire Chemical Division to
        Mangalam Drugs & Organics Ltd.
 
 1999   A new product namely Nimesulide was launched from Plant at 
        Plot No. 1203.
 
 2001   Two new products namely Amodiaquine Hydrochloride and 
        Amodiaquine were launched from Plant at Plot No.1203.
 
 2002   WHO-GMP approval for Chloroquine Phosphate I.P./B.P.
 
 2002   Awarded ISO-9000-2000 Management System Certificate from DNV.
 
 2003   WHO-GMP approval for Amodiaquine Hydochloride and 
        Amodiaquine U.S.P.
 
 2003
 
 -Awarded ISO-9000-2000 Management System Certificate from DNV.
 
 2005
 
 - Mangalam Drugs and Organics Ltd (MDOL) files prospectus with
 Securities Exchange Board of India to raise Rs 14.3 crore through a
 public issue to fund its expansion plans and support its growth in
 the anti-malarial segment. The offer is for 65,00,000 shares of Rs 10
 each at a price of Rs 22 and will remain open from April 19 to April
 26.
 
 - Shares of Mangalam Drugs & Organics Ltd made their debut on the
 Bombay Stock Exchange at Rs 30, higher than the issue price of Rs 22
 on May 23.
 
 2006
 
 -The Company has recommended a Final Dividend of Re 0.20 ps (2%) per
 Equity Share
 
 2009
 
 - Mangalam Drugs & Organics Ltd appointed Mr. Mukul Sukhani has been
 appointed as Additional Director on the Board of the Company.
 
 2014
 -Mrs Meenal Sukhani has been appointed as Additional Director on the
 Board of the Company.
 -The registered office of the company has been shifted from Princess
 Street Near Flyover Bridge, Marine Lines, Mumbai to  P.D. Mello Road,
 Mumbai- 400 020 to '3rd Floor, Rupam Building, 237, P. D. Mello Road,
 Mumbai - 400001, Mahrashtra.
 
 
स्रोत: रेलीगरे टेचनोवा

न्यूज़ फ़्लैश

  • MARKET CUES : FIIs ने कैश में `485 Cr की बिकवाली की
  • MARKET CUES : DIIs ने कैश में `770 Cr की बिकवाली की
  • MARKET CUES : FIIs ने F&O में `1762 Cr की बिकवाली की
  • MARKET CUES : इंडेक्स फ्यूचर्स में `360 Cr की बिकवाली
  • MARKET CUES : इंडेक्स ऑप्शंस में `1119 Cr की बिकवाली
  • MARKET CUES : स्टॉक फ्यूचर्स में `256 Cr की बिकवाली
  • HDFC LIFE : Standard life आज 3.53 Cr शेयर बेचेगा
  • YES BANK : `5,000 Cr की रकम जुटाने को बोर्ड मंजूरी
  • TATA STEEL/JSW STEEL : प्रोडक्शन में 70% तक की कटौती
  • ICICI Bank/Balrampur Chini : Auxilo Fin में 9.9% हिस्सा खरीदेगा ICICI Bk

अभी देखें

OUR WINNING PICKS

DID YOU INVEST?

INTRADAY PICKS!

(August 06, 2018)

AT (Rs)



GAIN (Rs)

ALL TIME WINNERS

RECO PRICE

PEAK PRICE

OUR PACKAGES

Super Combo

Powerful mix of both trader and investor packs with timely expert advice.

Technical

Designed especially for traders looking to tap the profit opportunities of volatile markets.

Fundamental

For all investors looking to unearth stocks that are poised to move.